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Abstract: Disorders of copper homeostasis are currently recognized across the life span. Their
recognition and links to human disease have spanned several decades, beginning with the recognition of a degenerative disorder in the offspring of sheep grazing in copper-deficient pastures,
through to the description of infants suffering from a progressive neurodegenerative disorder
characterized by epileptic seizures, developmental regression, failure to thrive, and an unusual hair
quality (giving the condition its distinctive label of “kinky hair disease”). In this review, we trace
the historical background and describe the biochemistry and physiology of copper metabolism and
transport, inheritance patterns, molecular genetics, and genotype–phenotype correlations based on
current understanding of the disorder. It is clear from the clinical presentations and variants that
disorders of copper homeostasis include phenotypes ranging from mild occipital horn syndrome
to intermediate and severe forms of classical Menkes disease. The symptoms involve multiple
organ systems such as brain, lung, gastrointestinal tract, urinary tract, connective tissue, and skin.
A multisystem disorder needs a multidisciplinary approach to care, as treatment interventions
permit longer survival for some individuals. Animal models have been developed to help screen
treatment options and provide a better understanding of these disorders in the laboratory. Finally,
we propose a multidisciplinary approach to promote continued research (both basic and clinical)
to improve survival, quality of life, and care for these conditions.
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The focus of this review is to highlight the role a multidisciplinary approach can play
in optimizing care of this multisystem lethal disease (Figure 1). The history of Menkes
disease (MD) dates back to as early as 1937 when Australian veterinary scientists
recognized an association between copper deficiency and a demyelinating disease of
the brain in the offspring of sheep grazing in copper-deficient pastures. Researchers
in the 1960s observing defective wool in affected sheep turned to the Australian Wool
Research Laboratories to establish a link between a copper-deficient diet and defective
hair formation. However, efforts to establish a causal relationship between a copperdeficient diet and wool quality remained inconclusive.
In 1962, Menkes et al at Columbia University, New York, NY, USA, described a
distinctive clinical syndrome comprising neurological degeneration in five affected male
infants of English–Irish heritage who showed unusual hair quality and failure to thrive.
These male infants appeared normal at birth through early infancy; subsequently, they
developed epileptic seizures and regression of developmental milestones progressing
to death between the age of 7 months and 3.5 years.1
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Figure 1 Multidisciplinary approach to MD.
Abbreviations: GI, gastrointestinal; MD, Menkes disease.

O’Brien and Sampson2 coined the term “kinky hair disease” and performed biochemical studies on frozen brain
tissues of two siblings, which demonstrated a reduction in
docosahexaenoic acid, the most highly unsaturated fatty acid
in brain. Disruption of mitochondrial function was postulated
as playing a possible role in this disorder on account of its
involvement in fatty acid oxidation.
Danks et al3 reported seven new cases of Menkes kinky
hair syndrome from five families seen over a period of
3 years in Melbourne, Australia. The mode of inheritance
in each pedigree was compatible with X-linked Mendelian pattern. Hypothermia, developmental delay, growth
failure, and very low serum copper were noted along with
the unusual hair quality of infants. Hairs from the scalp in
these infants appeared sparse, tangled, and lusterless with
rotational twists of “pili torti”, which were similar in texture
to the brittle wool of sheep raised on copper-deficient soil
in Australia (Figure 2). Sections of the scalp showed hair
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follicles deeply buried in the dermis with small, brittle, and
broken hair shafts.
MD, as it is currently known, is a lethal X-linked disorder
of copper metabolism with multisystem involvement. This
disease shows wide variability and clinical heterogeneity in
manifestations, ranging from a severe clinical course leading
to death in early childhood to a milder form termed occipital
horn syndrome (OHS) with connective tissue abnormalities
and longer survival.4 Patients with MD with intermediate phenotypes (5%–10%) characterized by later onset and milder
symptoms are also described.4,5 These variant presentations
are being better understood with evolving genotype–phenotype correlations.
Danks et al6 who carried out further research on this disorder used another term, “steely hair disease”. A number of
other eponyms, such as Menkes steely hair disease, Menkes
kinky hair disease, trichopoliodystrophy, and Menkes syndrome, have been used in scientific nomenclature.
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A

B
Normal hair

Pili torti
Figure 2 MD: (A) scalp shows “kinky hair”, (B) the inset shows “pili torti” and a normal hair strand under a high power microscope.
Abbreviation: MD, Menkes disease.

It is important to see how current understanding of different aspects of this disorder has been shaped by developments
in the fields of biochemistry, molecular genetics, pathology,
clinical presentation, and therapeutic interventions.

Epidemiology
The overall incidence of MD is reported to be 1 in 100,000–
250,000 births.7 However, regional geographic variation
is recognized. The incidence in Australia is reported to be
much higher than elsewhere at 1:50,000–100,000.5 A large
observational study reported the incidence as 1:300,000 in
Europe and 1:360,000 in Japan.7,8 The true incidence rate
of OHS is not reported in the literature (to the authors’
knowledge), but it is believed to be lower than that of MD.
Approximately 35–40 affected individuals are reported in
the literature, with the possibility that the condition may be
underdiagnosed.9,10
The vast majority of patients are male, while biological mothers are heterozygotes or carriers. The population
frequency of sporadic cases reported is compatible with the
one-third expected for an X-linked lethal disease with equal
mutation rates in egg and sperm, which implies a mutation
rate of 6.7×10-6/gamete/generation. However, the literature
reports few affected female patients, with most of them
having an X-autosome translocation with a breakpoint at
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Xq21.1, truncating ATPA7, which results in clinical manifestations and is attributed to random X inactivation.4,11 In
addition, there are few reports of females with milder symptoms who carry exon deletions (exon 6, 6–9, 1) or base-pair
substitutions.12–14

Biochemistry
The liver and kidney are the two organs in mammals that
have the highest concentration of copper.15 A healthy adult
body contains ~110 mg of copper, which is distributed in the
liver, kidney, brain, blood, and skeletal tissues.16 Vegetables,
animal proteins, and human breast milk are good sources of
copper.17,18 Under normal dietary conditions, the gastrointestinal (GI) tract in humans absorbs ~30%–40% of ingested
copper.18 Copper is present in various GI fluids such as
salivary, gastric, pancreatic, duodenal, and bile. The absorption of copper in humans occurs in two phases.15 In the first
phase, copper is absorbed from the distal small intestine and
reabsorbed into the circulation in its protein-bound form to
reach the liver and kidney. Once copper enters the body, it
is transported to different organs bound to plasma protein
carriers (ceruloplasmin, transcuprein, and albumin).19,20 In
the second phase, copper is transported from the liver (and
perhaps kidney) to other organs, including the brain, heart,
and skeletal tissue. A small amount of copper is secreted
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Table 1 Copper enzymes and their role in MD
Enzyme

Biological role

Associated symptoms of MD

Cytochrome
oxidase
Dopamine
β-hydroxylase

Cellular
metabolism
Catecholamine
production

Lysyl oxidase

Collagen and
elastin
cross-linking

CNS degeneration, ataxia
Respiratory failure
Hypothermia
Hypotension
Diarrhea
Cephalohematomas
Dysmorphic facial features
Emphysema, petechial
hemorrhage
Arterial defects
Skin, bone, and joint
abnormalities
Bladder diverticula, hernias
Hair abnormalities
CNS degeneration

Sulfhydryl oxidase Keratin
cross-linking
Super oxide
Free radical
dismutase
scavengers
Tyrosinase
Pigment formation Hypopigmentation

Abbreviations: CNS, central nervous system; MD, Menkes disease.

into the bile and is lost via the feces. Most of the copper
reaching the liver and kidney is returned to plasma bound to
ceruloplasmin, indicating that both organs may be important
sources of protein-bound forms of copper in circulation.16
Copper is an essential trace element that exists in two
different oxidation states, Cu+ and Cu++. These two states
play a crucial role in several copper enzyme-dependent metabolic processes. On the one hand, the capability of being
able to switch oxidation states is important in metabolic
processes, but on the other the same property can result
in the release of free radicals adversely impacting cellular
events. Therefore, maintenance of cellular homeostasis of
copper is vital.
There are various enzymes that require copper for important biological activities within the human body (Table 1).
These are cytochrome c oxidase (COX) for cellular respiration; dopamine β-hydroxylase for biosynthesis of neurotransmitters; lysyl and sulfhydryl oxidase for collagen, elastin, and
keratin cross-linking; tyrosinase for pigmentation; and superoxide dismutase for free-radical scavenging. Ceruloplasmin,
a key circulating copper-binding protein has a crucial role in
the regulation of copper and iron homeostasis.5,21 The impact
of copper deficiency in the nervous system is significant to
the current understanding of neuronal dysfunction at a cellular level and its effects on neuropathogenesis of MD. Low
levels of brain copper in MD affect catecholamine pathways,
leading to abnormal catecholamine metabolite levels in blood
and body fluids. While norepinephrine levels were found to
be normal in the infants studied, the ratios of the dopamine
metabolites, dihydroxyphenylacetic acid (DOPAC) and
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the catecholamine precursor dihydroxyphenylalanine, to
neuronal metabolite of norepinephrine, dihydroxyphenylglycol (DHPG), were increased above control values, suggesting
partial dopamine β-hydroxylase deficiency. This forms the
basis of a newborn screening test, which is discussed in the
following sections. Furthermore, a significant reduction in
brain COX activity leads to intracerebral lactic acidosis and
other mitochondrial abnormalities in MD, which points to
insufficiency in cellular bioenergetics as a contributor to
neuronal dysfunction.
Gene expression profiling in the single postmortem study
of a patient with MD identified dysregulation of 394 genes in
the cerebellum and 121 genes in the cerebral cortex. At least
30 genes were found to be common to both the cortex and
cerebellum. These genes encode enzymes in the tricarboxylic
acid cycle and oxidative phosphorylation (mitochondrial
adenosine triphosphate [ATP] synthase), as well as affect
ribosomal translation mechanisms, signal transduction,
and immune responses. It has also been suggested that the
ATP7A protein plays a role in the modulation of excitotoxicity. In vitro studies of mouse models of MD indicate that
atp7a-mediated release of copper from an intracellular pool
in response to calcium-mediated N-methyl-d-aspartate receptor activation is impaired, leaving the neuron vulnerable to
excitotoxic injury.
Therefore, in MD, a copper-deficient state is characterized by a multisystem involvement that reflects biochemical
perturbation mediated through copper deficiency states that
affect enzymatic function involving critical biological processes. The resulting deficits in neurotransmitter function,
energy metabolism, and excitotoxicity play key roles in the
neurological manifestations of the disease.

Copper metabolism in the cell
Copper uptake across plasma membrane is dependent on
membrane transporter (CTR1).22 Copper is bound to various
proteins such as metallothionein, glutathione, or copperspecific chaperones that have a role in copper loading of
enzymes.23,24 Three types of copper chaperones are known:
ATOX1, COX 17, and CCS. ATOX1 helps copper to reach
the trans-Golgi network, where it is incorporated into two
copper-specific ATPases: ATP7A and ATP7B.25 Dysfunction
of these two ATPases causes MD and Wilson disease, respectively. ATP7A is expressed in almost every organ except liver,
while ATP7B is expressed predominantly in the liver. This
explains why MD is a systemic disease and Wilson disease
is primarily a liver-specific disease with some neurological
and ophthalmological involvement.
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Table 2 Functions of ATP7A: a multitasking protein in the nervous system
Function

Evidence

Reference

Maintenance of axonal outgrowth and synaptic integrity
ATP7A traffics to hippocampal glutamatergic neurons in
response to NMDA receptor activation. Calcium entry
following such activation is accompanied by copper efflux
ATP7A participates in the provision of copper to dopamine
β-hydroxylase to facilitate conversion of dopamine into NE
ATP7A participates in the maintenance of cholinergic neurons
in the peripheral nervous system

Animal model
Animal model

El Meskini et al31
Schlief et al32

Based on CSF neurotransmitter profiles in affected individuals
with MD
Human and yeast models. Unique ATP7A missense mutations
(p.P1386S and p.T994I) in males with distal motor neuropathy
which do not alter the transporters critical functions but
impaired trafficking despite normal ATP7A protein and mRNA
levels. Neuropathy occurs without overt signs of systemic
copper deficiency
Angiotensin-II-associated hypertension
Animal model suggests that angiotensin-II-induced hypertension
is regulated through extracellular superoxide dismutase SOD3
activity through the increase in copper delivery via the ATP7A
protein
Cisplatin resistance
Cell line studies suggest enhancement of cisplatin toxicity in cells
overexpressing ATP7A alone or on pretreatment with O(6)benzylguanine
Bactericidal activity of macrophages
Animal model suggesting a role of ATP7A at the host pathogen
interface
Hepatic mobilization of copper in the event of a cardiac copper Animal model suggesting a regulatory mechanism for copper
deficiency
mobilization from the liver to the heart in response to tissue
demand that is mediated through ATP7A protein

Kaler et al33
Kennerson et al34

Qin et al35

Rabik et al36

White et al37
Kim et al38

Abbreviations: CSF, cerebrospinal fluid; MD, Menkes disease; NE, norepinephrine; NMDA, N-methyl-d-aspartate.

COX 17 directs the copper into mitochondria where other
copper metalation proteins such as COX 11, SCO1, and
SCO2 are present,26 while CCS directs copper to superoxide
dismutase, which resides in the cytosol or the mitochondria.27
ATP7A and ATP7B have important roles in ATP-driven cellular efflux of copper as described in the following section.28

 etallochaperones to ATP7A and ATP7B, eventually particim
pating in the metalation of cuproenzymes.
ATP7A is a multitasking protein that is involved in a
multitude of functions ranging from axonal outgrowth, synaptic integrity, responses to N-methyl-d-aspartate receptor
activation, and other functions as listed in Table 2.

Regulation of copper transport

Molecular genetics

The ATP7A mRNA is expressed in several human tissues, but
is notably low or absent in the liver, while the ATP7A gene
product is a transmembrane protein localized to the Golgi
network. Under normal physiological conditions where the
copper concentration in the body is normal, ATP7A remains
confined within the trans-Golgi network and continues to
transport copper to the copper-dependent enzymes. However, when total intracellular copper stores increase, ATP7A
relocates to the cell membrane to promote copper efflux.29,30
At the blood–brain barrier, ATP7A tends to traffic to the
basolateral membrane promoting delivery of copper from
blood to the brain, while in certain specialized epithelial
cells such as the choroid plexus, the protein localizes to the
apical membrane. Once copper reaches the cerebrospinal
fluid, it forms complexes with albumin and amino acids
(histidine). It is then imported into neurons through specific
copper importers (DMT1 and CRT1) and delivered through

Early studies in understanding the genetics of MD came
through the identification of a defect in copper metabolism.39 Copper concentrations were elevated in the cultured
fibroblasts of affected males and heterozygote carriers. Similarities between the clinical and biochemical phenotype in
humans and the “mottled” mouse (Mo) and the knowledge
that mottled gene mutations were close to the phosphoglycerate kinase (PGK) gene, which in humans is located on the X
chromosome, led to the conclusion that the gene for MD was
likely located on the X chromosome. Further, linkage studies
using restriction fragment length polymorphism markers in a
large kindred and studies on a female patient with both this
disease and an X- autosome translocation with karyotype 46,
X, t(X; 2) (q13; q32.2) indicated that the Menkes gene maps
to a small subregion of band Xq13.2-q13.3 proximal to the
PGK1 locus,40 which was also confirmed by additional finemapping studies.41 A yeast artificial chromosome clone was
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isolated spanning the breakpoint region, and cDNA libraries
were scanned using phage subclones from the breakpoint
region. An 8 kb transcript from a gene at the breakpoint
showed diminished hybridization in patients with MD. Partial sequencing identified metal-binding motifs supporting
the likelihood that this was indeed the candidate gene. The
ATP7A gene is located at the chromosome locus Xq13.3 and
has eight transmembrane segments and six copper-binding
sites/domains, additional domains for phosphatase, phosphorylation, transduction, and ATP binding.
Using restriction enzyme mapping, exon identification,
and sequencing techniques, 23 exons were identified spanning a 140 kb region as well as the intron–exon boundaries
defining the ATP7A gene. The gene was found to bear a
strong sequence homology at the 3´ region with the Wilson
disease (Wnd) gene and divergence for a third of the gene
at the 5´ region, suggesting a common ancestral origin from
an evolutionary perspective. Further characterization of the
candidate gene for Menkes (MNK) disclosed that the gene
codes for a 1,500 amino-acid protein, which is predicted to
be a P-type cation-transporting ATPase (ATP7A) similar to
a bacterial copper-transporting ATPase.42–44
Most of the clinical phenotypic features were already
attributable to malfunction of copper-containing enzymes that
were deficient in copper, and cell studies from patients with
MD had already been demonstrated to accumulate increased
amounts of copper attributable to a reduced efflux of the
copper ion. These findings were in line with the discovery
of the candidate gene product bearing a homology to heavy
metal-binding ATPases in bacteria and man. With these
discoveries, MD has come to be understood as a disorder of
copper homeostasis.

Genotype–phenotype correlations
Pathogenic mutations in ATP7A result in a variety of
clinically recognizable phenotypes associated with copper
transport disorders (MD, OHS, and the ATP7A-related distal
motor neuropathy). The degree to which residual ATP7A
function is maintained determines the severity of the clinical
phenotypes. Mutations of every variety have been associated
with MD; the majority are de novo and private. Exon deletions can be detected by the multiplex ligation-dependent
probe amplification as an initial DNA test, while smaller
intragenic mutations can be examined by polymerase chain
reaction amplification and sequencing of coding exons using
genomic DNA.
More than 311 different mutations have been reported
in patients with MD. 45 Deletions or insertions (22%),
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large gene deletions (22%), duplications, missense (17%),
nonsense (18%), and splice junction mutations (18%)
have all been described. A 700-nucleotide region involving exons 7–10 seem to be associated with a significant
proportion of pathogenic mutations resulting in MD.46–48
Those mutations that result in a severe truncation of the
gene product and significant loss of function likely result
in MD; hypofunctional splice site resulting from aberrant
splicing and missense mutations with retention of protein
function are associated with milder phenotypes. With
0%–15% residual function in ATP7A activity, the resulting phenotype is MD; higher degrees of function up to
30% result in the milder OHS phenotype, while 60%–70%
residual function is associated with late-onset distal motor
neuropathy.49
Although the majority of affected individuals are males,
heterozygous females tend to be carriers based on skewed
inactivation of the X chromosome; rarely females with chromosomal translocations have been reported to be affected
and manifest symptoms.
Of all the different mutations described,50 two mutations
resulting in MD are amenable to early treatment with copper
(Gly666Arg and Gly727Arg). Not much is known about the
treatment response of remaining missense mutations.
The OHS is an allelic disorder of MD that results from
exon skipping and aberrant splicing, although missense
mutations without aberrant splicing are also described.
Less frequently, deletions affecting the promoter region or
resulting in a leaky “splice junction” may also lead to the
milder OHS phenotype. The mutations seem to result in a
significantly greater degree of retention of ATP7A activity
than those leading to MD.
The third phenotype of ATP7A-related distal motor
neuropathy is distinctive in that there are no overt copperrelated metabolic/biochemical abnormalities. The mutations
underlying this phenotype are missense mutations affecting
amino acids within or near transmembrane segments of
the protein. The resulting amino acid substitutions appear
to affect trafficking of the protein to distal axons and the
resulting deficiency of copper-dependent enzymes critical
to the maintenance of integrity and function of the motor
neuron and its axons. The precise mechanism underlying the
pathophysiology of this unique disorder of copper transport
and metabolism remains to be elucidated.51–54

Clinical presentation of MD
The key clinical features of classical MD, intermediate forms,
and OHS are summarized in Table 3.
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Table 3 Manifestations of MD
Symptoms and laboratory
findings in MD

Classical

Clinical
Facial dysmorphism
+
Neurological abnormalities
Intractable seizures
++
Dysarthria
–
Ataxia
–
Developmental delay
++
Hypotonia
++
Dermatological abnormalities
Hair abnormalities
++
Hypopigmented skin
+
Cutis laxa
+
Bony changes (osteoporosis, rib
++
fracture, wormian bone in skull)
Hypothermia
+
Bladder diverticula
+
Recurrent UTI
+
Diarrhea
+
GORD, polyp, hiatus hernia
+
Retinal degeneration
+
Biochemical
Low serum copper and
+
ceruloplasmin
Abnormal plasma/CSF
+
catecholamines
Radiological
X-Ray skull: presence of wormian ++
bones
CT/MRI changes in brain: global
++
cerebral atrophy, cerebellar
atrophy, focal changes in
temporo-occipital, frontal
parietal lobes, subdural effusion,
leukoencephalopathy, and abnormal
vasculature
Tortuosity of intracranial vessels
++

Intermediate

OHS

±

+

–

–

++
++
±
+

±
+
±
±

+
+
+
+

±
–
++
+

±
+
+
+
?
?

±
+
+
+
?
?

+

+

?

?

–

–

±

±

?

?

Notes: ++ is very much likely; + is likely; – is not likely; +/– may or may not be
likely; ? is questionable.
Abbreviations: CSF, cerebrospinal fluid; CT, computed tomography; GORD,
gastro-oesophageal reflux disease; MD, Menkes disease; MRI, magnetic resonance
imaging; OHS, occipital horn syndrome; UTI, urinary tract infection.

Classical form of MD
Pregnancy and labor are usually uncomplicated, and most
affected males born with MD have normal anthropometric measures at birth. However, early features noted with these neonates
are: hypothermia, cephalohematomas, persistent hyperbilirubinemia, hypoglycemia, and feeding difficulties.30,55,56 Such
infants are also recognized to carry subtle dysmorphic facial
features such as frontal or occipital prominence, pudgy cheeks
with broad nasal bridge, and micrognathia and often may appear
dull and expressionless.55 Various types of congenital malformations are known to be associated with MD. In one study, 35
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patients with MD were reviewed and 14 were found to have
congenital m
 alformations. Out of these 14 patients, eight had
minor congenital malformations including high arched palate,
micrognathia, congenital microblepharia, entropion, and a flat
occiput. The remainder had major congenital malformations
including cerebellar hypoplasia, cystic white-matter changes in
the brain, congenital complete A–V block, and cystic changes
in the arachnoid membranes in the lungs.57
Respiratory infections such as pneumonias are reported
in the literature as one of the causes of severe morbidity or
mortality in MD.58,59 An anecdotal report of a 19-month-old
male infant who died of MD revealed, at necropsy, bilateral
diffuse panlobular emphysema in the lungs.60 A similar case
is also reported in an infant presenting with respiratory illness from the age of 9 months, in whom chest radiography
revealed progressive generalized hyperinflation and increased
cystic spaces. An autopsy at 14 months showed severe diffuse panlobular emphysema with large bullae along with
abnormal pulmonary vascular development.56 The authors
hypothesized that deficiency of the copper-dependent
enzyme, lysyl oxidase, leads to abnormalities in quality and
quantity of elastin, which forms an important element in
connective tissue formation, leading to aneurysmal dilatation
and emphysema in MD.
GI manifestations in MD are reported infrequently, and
there may be an under-recognition of involvement of the
GI tract. Gastric polyps, gastroesophageal reflux disease,
and colonic diverticula are reported in the literature.56,61,62
Hiatus hernia has been reported to be associated with MD
and OHS.63,64 Progressive sliding hiatus hernia was noted
in a 19-month-old male infant with MD, which progressed
rapidly, requiring surgical intervention.63 An additional two
infants with MD have been described in whom severe GI
bleeding secondary to gastric polyps was noted. One of
these patients died of severe hemorrhage.65 In addition to
GI manifestations, an unusual presentation of MD with
hepatomegaly in a 4-month-old infant who was known to
carry a missense mutation of his ATP7A gene (Gly727Arg
mutation) has also been reported. The liver biopsy revealed
nonspecific cholestasis and focal necrosis.66
Several connective tissue abnormalities are described in
MD, which are considered to be secondary to reduced activity
of lysyl oxidase, a copper-dependent enzyme important for
cross-linking collagen and elastin.67,68 These include pectus
excavatum, pectus carinatum, the presence of wormian bones
in skull, osteopenia, and spontaneous fractures of long bone.59
Most patients with MD have mottled hypopigmented and pale
skin presumably due to tyrosinase deficiency.69
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The scalp hairs (Figure 2) may appear normal at birth,
but by 2–3 months of age they become kinky, coarse, sparse,
brittle, and hypopigmented, which are characteristic of
MD.70,71 Microscopic examination of the hair reveals various abnormalities and even aids in the diagnosis of milder
form of the disease.72 Several hair shaft abnormalities have
been reported, with pili torti (twisted hair) being the most
common; trichorrhexis nodosa (fracture of the hair shaft
at regular intervals), monilethrix (varying diameter of hair
shafts), trichoclasis (hairs are broken off from 6 mm to 8 mm
from the skin), and trichoptilosis (splitting of the shaft of the
hair) have also been reported.72,73
The neurological manifestations of MD are also varied.
Epileptic seizures are one of the most common and wellrecognized features of MD. Most patients develop treatmentresistant forms of seizures by ~2–3 months of age.74,75 Many
different kinds of seizures have been described in affected
infants and children with MD. Seizures in MD can be triggered by the acute stress secondary to severe infection, a
febrile event, or could be preceded by nonconvulsive seizures
associated with recurrent episodes of apnea.76–79 A case series
(Bahi-Buisson et al) focused on electroclinical features in MD
and described the natural progression of epilepsy in MD; the
key features are summarized in Table 4.
Seizures and neurological regression usually become
apparent at 6–8 weeks of life. Three stages are identified in
the natural history of the progression of epilepsy in MD. Electroencephalography (EEG) abnormalities may antedate the
appearance of seizures, as early as 2 months of life. The three
stages are as follows: 1) an early stage at the age of 3 months
with focal seizures progressing to status epilepticus, 2) an
intermediate stage (6–11 months) where epileptic spasms,
including West syndrome accompanied by EEG changes of
hypsarrhythmia, develop; myoclonic seizures as a presenting
symptom have also been reported, and finally, 3) a third late
stage that is characterized by the emergence of multifocal

seizures, tonic spasms, and myoclonus encountered in infants
with a mean age of ~20–25 months.78,80,81 Typical interictal
and ictal EEG findings are described in an earlier article78,81
(Figure 3).
EEG abnormalities correlate with molecular defects, as
shown in a series of 24 patients with MD, where patients with
missense and leaky splice junction mutations were found to
have normal EEGs. On the other hand, large deletions, small
deletions, nonsense mutations, and canonical splice junction
mutations were associated with significant EEG abnormalities in >50% of the cases.47,74
Presymptomatic diagnosis and early treatment may
improve brain electrical activity. This was demonstrated in
a study which looked at 24 patients with MD. In that study,
the authors reported that patients were started on copper
supplementation soon after the diagnosis (≤6 weeks of
age) and they noted clinical seizure in only 12.5% of the
patients, and they found that 46% had at least one abnormal
EEG tracing.81 Early diagnosis and treatment are closely
correlated with the genesis of epilepsy in MD. A study in
2008 demonstrated that copper replacement within 22 days
of life in 12 newborns diagnosed with MD had improved
the clinical outcome.82
Neuropathologic changes in MD are also distinct.
There is diffuse cerebral and cerebellar atrophy that is a
consequence of volume loss of both white and gray matter. Widespread histological abnormalities noted include
neuronal loss and gliosis within cortical gray matter, cystic
infarction in the basal ganglia, loss of Purkinje cells in
cerebellum, and spongy changes in cerebral white matter
along with loss of myelin sheaths and axons.83,84 The muscle
shows ragged red fibers on histology, with pleomorphism of
mitochondria and cristae under the electron microscope.82
Vascular abnormalities are noted in the cerebral arteries;
these vessels appear thin walled, ectatic, and tortuous59,84
(Figure 4).

Table 4 Evolution and progression of epilepsy in MD
Epilepsy course (stage)

Type of seizure

Median age

EEG findings

Outcomes

Early

Focal clonic and
status epilepticus

3 months

Partial seizure control in
nine of the 12 patients

Intermediate

Intractable infantile 10 months
spasm
Multifocal, myoclonic 25 months
seizure and tonic
spasm

Ictal EEG showed slow spike wave and slow
wave in posterior region; interictal EEG showed
multifocal and polymorphic slow waves or mixed
slow wave spikes
Modified hypsarrhythmia; different irregular slow
waves and spike waves
Multifocal high-amplitude activity; mixed irregular
slow waves

Late

Six patients died at a
median age of 15 months
The remaining six
patients died at a median
age of 3.6 years

Note: Data adapted from Bahi-Buisson et al.78
Abbreviations: EEG, electroencephalography; MD, Menkes disease.
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as hypothermia, jaundice, and feeding difficulties. In addition, they may present with umbilical and inguinal hernias.
The findings in contrast to classical MD are connective
tissue abnormalities such as, wrinkled, loose skin and bony
abnormalities of flat and long bones, including o steoporosis.
The distinct radiologic feature of OHS is symmetric exostoses protruding from occipital bones, leading to the designation of “occipital horn”. The diagnosis of OHS is often
delayed until 5–10 years of age due to milder and subtle
symptoms. Usually, the early signs that bring these patients
to medical attention are intractable diarrhea and recurrent
urinary tract infection, which are secondary to bladder
diverticula. Intellectual capabilities in these patients are
described as low to borderline normal. Motor development
is also delayed secondary to muscular hypotonia and other
connective tissue disorders. Patients with OHS can remain
alive until adulthood.5,86

Intermediate forms

C

Between classical MD and OHS lies another group of
disorders that is a milder form of MD with late presenting
symptoms.87 These patients have abnormal hair (pili torti),
variable connective tissue manifestations such as lax skin
and joints, and characteristic facial features. They are also
reported to have milder neurological presentations compared
to MD and commonly have ataxia, dysarthria, and mild intellectual disabilities.88,89

Diagnosis

Figure 3 EEG segments from patient with MD.
Notes: (A) Anterior–posterior bipolar montage shows ictal rhythm corresponding
to a focal seizure originating in the right mid to posterior temporal regions
(15 mm/s, sensitivity at 15 μV/mm). (B) Ictal rhythms showing rhythmic generalized
spike and slow waves (time base at 30 mm/s, sensitivity at 20 lV/mm). (C) Late stages
– interictal background rhythms are slow for age, with multifocal independent spikes
and spike and wave complexes (time base at 30 mm/s, sensitivity at 20 lV/mm).
Abbreviations: EEG, electroencephalography; MD, Menkes disease.

Occipital horn syndrome
OHS is considered to be the mildest form of MD with a
few male patients with overlapping features of classical
and/or mild MD and OHS reported.85 Patients with OHS
have very similar presentations as with MD at birth, such
Journal of Multidisciplinary Healthcare 2016:9

Early diagnosis of MD is challenging because clinical
features and biochemical markers may be nonspecific and
unreliable. Clinical presentations such as hypothermia,
hyperbilirubinemia, and feeding difficulties are nonspecific
and may present in neonates with other conditions such as
sepsis. Serum copper and ceruloplasmin levels may be low
in normal healthy newborns and hence not a good predictor
in the early diagnosis of MD. Molecular analysis confirms
the diagnosis. There are >300 different mutations reported in
MD, which include missense and nonsense mutations along
with deletion and insertions of one or more base pairs leading
to frameshift and splice site mutations.90–92

Newborn screening
Currently, there are no newborn screening programs that
are routinely screening for MD in countries where newborn screening programs exist for other genetic/metabolic
disorders. However, a role for newborn screening can be
rationalized on the basis of the evidence that early diagnosis
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Figure 4 MRI of the brain (A) and MRA (B) from the same patient.
Notes: (A) Generalized fronto-temporal cerebral atrophy resulting in exposure of the insula, and thinning of the subcortical white matter (arrows). (B) Tortuosity of
intracranial vertebral arteries (arrow).
Abbreviations: L, left; MRA, magnetic resonance angiography; MRI, magnetic resonance imaging; R, right.

seems to make a difference in survival and outcome in some
patients with MD.82 Measurement of neurochemicals such as
dopamine, norepinephrine, DOPAC, and DHPG in the plasma
and cerebrospinal fluid is reported to be highly specific and
sensitive test to diagnose MD in the early neonatal period.
The ratio of DOPAC to DHPG reflects the deficiency of
dopamine β-hydroxylase activity.82,93
An argument can thus be made for the inclusion of MD
into neonatal screening programs based on the detection and
measurement of plasma dopamine, norepinephrine, DOPAC,
and DHPG using blood dot specimens.

Prenatal diagnosis
Prenatal diagnosis is available for women who are MD carriers, by chorionic villus sampling and analyzing copper uptake
in cultured fibroblasts in pregnancies at high risk, and where
the mutation is unknown. If there is an affected individual
in the family with a known mutation, then the pathogenic
mutation can be identified through mutation analysis.94,95

Animal models
Much of our understanding about MD stems from animal
models.96 Early studies have focused on the mottled mouse that
carries mutations in the Atp7a gene resulting in a mottled coat
in heterozygous females. The murine gene locus Atp7a and the
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human homolog ATP7A are located on the X chromosome,
and share >80% homology. Both gene products on sequence
alignment show highly conserved amino acid sequences
within functional domains.97 These similarities extend to the
ATP7A proteins in zebrafish and fruitfly. The initial description of the mottled mouse appeared in 1953,98 and the defects
in copper transport were described in these mutant mice by
Hunt in 1974.99 Currently, 109 mottled alleles are known in
the Mouse Genome Informatics database. These have arisen
spontaneously or by chemical, radiation, or targeted mutagenesis. Phenotypic severity in these models involving male mice
varies from lethality in utero and death in 3 weeks to mice
that survive a few postnatal months. A detailed assessment of
these mutants is beyond the scope of this review. The reader is
referred to an outstanding review on the subject.97 It is however
important to summarize important insights that have been
gained. Mutations that confer embryonic lethality completely
abolish residual protein activity, suggesting a critical role for
copper in embryogenesis. “Brindled”, “mosaic”, and “macular” are strains that have been studied, and mutations in this
group are missense or in frame deletions that lead to reduced
synthesis of the mutant protein with reduced residual activity.
Hemizygous males show characteristic features of severe copper deficiency, but survive beyond 3 weeks of postnatal life.
Mutants that include “viable brindled” and “blotchy” survive a
Journal of Multidisciplinary Healthcare 2016:9
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few months and develop features of atypical MD and/or OHS
particularly connective tissue abnormalities. Aortic aneurysms
(viable brindled), emphysema, osteoarthrosis, abdominal
aneurysms (mottled), infertility (common to both mutants),
and hypopigmentation are among the features shared between
the models and human disease.
These mice have also served as models for exploring treatments. Copper replacement therapy given early to mottled
mice improves survival, and the combination therapy with a
copper chelator diethyldithiocarbamate has shown promising results.100–102 Treated animals showed improved survival,
increased copper levels in the brain, improved locomotion,
and greater body mass.
Transgenic mice models have also been developed from
the brindled strain, where human ATP7A was expressed in
a truncated form using recombinant adenovirus encoding
the truncated gene that was administered by intraventricular
injections. The treated mice survived longer and demonstrated higher dopamine monooxygenase activity in the brain
along with improved neuromuscular strength and balance.
Mottled mice have also proven invaluable in studying
the interaction between copper and iron metabolism suggesting intricate linkages that impact hematopoiesis and red
cell turnover.
Other animal models include the zebrafish (Danio rerio)
and the fruitfly (Drosophila melanogaster). In the zebrafish,
calamity mutants generated by chemical mutagenesis have
served as novel vertebrate models of MD.103 The phenotypic
effects extend to lack of pigmentation and defects of the
notochord. Morpholinos (oligonucleotides that can target
RNA sequence of interest) can correct aberrant splicing in
the embryonic calamity mutant zebrafish and effect a rescue
by leading to the production of normal Atp7a protein as in
the wild type.104
The fruitfly has been studied as a model for many neurodegenerative disorders. A null mutation in the DmATP7
gene has resulted in a classical model for MD.105 The mutant
fruitfly is extremely lethargic, while larvae are small and
hypopigmented. Another model using conditional silencing
of DmATP7 only in the digestive tract results in enhanced
lethality and 50% survival to adulthood. The survivors show
small brain size, but normal morphology as far as pigmentation is concerned. They are also sensitized to oxidative
stress, a feature of MD that has been attributed to reduced
superoxide dismutase activity.106
Animal models can thus be used to develop therapeutic
approaches through genetic modification as well as screening
of compounds that affect copper metabolism.
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Management
MD is a fatal disorder with death usually occurring between
6 months and 3 years of age as a result of neurological
deterioration, poor feeding, aspiration, or respiratory infections. Those patients with less severe disease have a better
survival rate with copper supplementation; however, the
outcome depends on the severity of the ATP7A mutation
and the residual function of ATP7A protein. Treatment with
copper supplementation is most likely effective in those
cases where the mutated protein retains the ability to transport copper across the blood–brain barrier. In patients with
MD where the mutation leads to severe disease, treatment is
ineffective.82 Although treatment has not yet been known to
reverse the neurological damage, a small subgroup of patients
with MD manifesting milder symptoms have been reported
to have better outcome.107
There have been few reports of long-term survival with
MD. Tchan et al108 reported a patient with MD at 34 years
having received copper supplementation for >30 years and
having only mild intellectual impairment. Another patient
with MD receiving copper supplement was reported to have
survived till the age of 13.5 years.109
Parenteral copper administration is considered the mainstay in treatment protocols for MD as oral preparations are
not shown to be effective. Most researchers have used copper
histidinate for treating MD.110,111 Subcutaneous administration
of copper histidinate can normalize circulating blood levels
of copper and ceruloplasmin and may replete brain copper.112
Prasad et al113 reported the correction of biochemical
markers in a patient with MD using subcutaneous cupric
chloride. They reported restoration of serum copper and ceruloplasmin along with clinical improvement in skin color and
quality of hair; however, neurological status did not improve.
Early screening and prompt medical intervention are
crucial in MD. Patients who were diagnosed and received
early treatment with copper (within 25 days) had a much
better neurodevelopmental outcome compared to late onset
of treatment (228 days).114 Kaler112 conducted a clinical trial
using copper histidinate for MD, looking at somatic growth
and neurodevelopmental outcome in 60 patients. The findings in this trial suggested that those who received copper
histidinate before the onset of symptoms showed significant
improvements in gross motor, fine motor/adaptive, personal–
social, and language development in comparison to those who
were symptomatic at the time of diagnosis. The mortality rate
at the age of 3 years was also reported to be higher in the
symptomatic group.112 Other studies have also reported similar
outcomes.115,116 Christodoulou et al111 reported improvement in
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muscular tone and seizure activities in four patients with MD
who they followed as a result of early treatment with copper
histidine for 10–20 years. However, the response to connective
tissue abnormalities associated with MD was noted to be poor.

Multidisciplinary approach to MD
MD is a multisystem disorder that has no cure. Current published data on MD suggests that there is wider age dependent
variability in phenotypes at presentation.54 However, contrary
to previous notions of shortened life expectancy, patients
currently seem to have better outcomes in terms of survival.
A multidisciplinary approach can improve the quality of life
and holistic care for patients with MD (Table 5).
Neonatal nurses or neonatologists can play an important
role in the early recognition of subtle signs and symptoms such
as hypothermia, unusual hair, and dysmorphic facial features.
This can facilitate early referral and diagnosis, supporting the
initiation of copper supplementation as required. Outside the
neonatal unit, nurses or doctors in clinics or in the emergency
department can come across this disorder. Children may present with macrocephaly with subdural hematoma, occasionally
mimicking a diagnosis of shaken baby syndrome, needing
further evaluation.117 Patients with MD may also present with
macrocephaly and seizures closely simulating neurological
disorders such as leukodystrophies and Canavan or Alexander
diseases118,119 prompting early referral to pediatric neurologists
and genetic metabolic specialists. These patients may also
present to developmental or neurology clinics with a history
of delayed or regressing milestones.
Interventions involve the institution of copper replacement therapy and the potential use of chaperones in the future.
Failure to thrive should be assessed by a feeding team in
association with a dietitian who can provide a feeding plan
to optimize growth. Occupational therapists and physiotherapists can provide detailed assessment and management
strategies for those patients who have problems with their
tone and mobility. These can include a range of movement
exercises, ways to prevent contractures and bedsores as well
as assisting in formulating plans for activities of daily living.
Parents of patients with MD can benefit from education on
how to give injections and take care of the patients at home.
Anticipatory guidance about creating a safe environment, medications to alleviate symptoms, and supportive interventions for
seizure management can be provided through nurse educators.
Genetic counselors have a role in providing parental
reproductive risk counseling and prenatal diagnosis. Parents
benefit through the sharing of information through support
groups and social media connectivity. It is often noted that
families taking care of patients with very high needs face
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Table 5 Multidisciplinary management in MD
Clinical care issues in MD by age and
stage of disease
Neonatal period
• Early diagnosis, referral, and treatment
• Recognize early and subtle signs
and symptoms (facial features,
hypothermia, hair changes),
investigate and confirm diagnosis so
as to start treatment with copper as
early as possible
• Newborn care
• Maintaining temperature by increasing
room temperature, keeping head
covered, providing care with minimal
skin exposure, limiting repeated blood
sampling
• Optimizing feeds: feeding assessment:
patients may need N/G feeding
• Family education and emotional and
financial support
Later care ( supportive)
• Growth and nutrition
• Feeding assessment: providing option
of N/G feeding or G-tube feeding
• Preventing aspiration: need for
suction equipment and education
• Seizure optimization
• Safe environment, medications to
alleviate symptoms. Education and
anticipatory guidance
• Developmental assessment
• Intellectual/cognitive assessment,
range of movement assessment,
preventing contractures, and bed
sores
• Other supportive care
• Home care and education
• Respite and other services
• Genetic counseling

Multidisciplinary
services
• Neonatologist/
pediatrician
• Neonatal nurse
• Geneticist
• Biochemist
• Dietitian

• Nurse
• Social worker

•
•
•
•
•
•
•
•
•
•
•
•

Dietitian
Nutritionist
SLP
Gastroenterologist
Pediatrician
Neurologist
Developmental
pediatrician
Occupational therapist
Physiotherapist
Occupational therapist
Genetic counselor
Community nurse

Abbreviations: G-tube, gastric tube; MD, Menkes disease; N/G, nasogastric;
SLP, speech and linguistic pathologist.

emotional, financial, and social challenges. A social worker
can assist these families by providing counseling services
and financial support and also help link families to support
groups and the national organization of rare disorders.

Conclusion
The past several decades have witnessed rapid and tremendous
advances in our understanding of MD and related disorders
of copper homeostasis. This review highlights the advances
and breakthroughs in the basic science and molecular genetics
leading to improved recognition and diagnosis. Early diagnosis
has been shown to improve survival, and the availability of
copper replacement therapy is a step forward. Multidisciplinary
research and care teams can not only help in the development
Journal of Multidisciplinary Healthcare 2016:9
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of clinical trials on MD in the future but also further the goal
of improving quality of life for survivors. The work in basic
science through the development of animal models holds great
promise for future therapies for this otherwise fatal disorder.

Acknowledgments
The authors would like to thank CA Rupar, PhD, Professor, Departments of Pathology and Laboratory Medicine,
Biochemistry, and Pediatrics, for his critical review of the
manuscript, comments, and suggestions. There was no funding source for this review.

Disclosure
Asuri N Prasad has received honoraria from EMD Serono Inc
in the last financial year. The authors report no other conflicts
of interest in this work.

References

1. Menkes JH, Alter M, Steigleder GK, Weakely DR, Sung JH.
A sex-linked recessive disorder with retardation of growth, peculiar
hair, and focal cerebral and cerebellar degeneration. Pediatrics.
1962;29:764–779.
2. O’Brien JS, Sampson EL. Kinky hair disease. II. Biochemical studies.
J Neuropathol Exp Neurol. 1966;25(4):523–530.
3. Danks DM, Campbell PE, Stevens BJ, Mayne V, Cartwright E.
Menkes’s kinky hair syndrome; an inherited defect in copper absorption with widespread effects. Pediatrics. 1972;50(2):188–201.
4. Timer Z, Horn N. Menkes Disease: recent advances and new aspects.
J Med Genet. 1997;34(4):265–274.
5. Tumer Z, Moller LB. Menkes Disease. Eur J Hum Genet. 2010;18(5):
511–518.
6. Danks DM, Cartwright E, Stevens BJ, Townley RR. Menkes’ kinky hair
disease: further definition of the defect in copper transport. Science.
1973;179(78):1140–1142.
7. Tønnesen T, Kleijer WJ, Horn N. Incidence of Menkes disease. Hum
Genet. 1991;86(4):408–410.
8. Gu YH, Kodama H, Shiga K, Nakata S, Yanagawa Y, Ozawa H.
A survey of Japanese patients with MD from 1990 to 2003: incidence
and early signs before typical symptomatic onset, pointing the way to
earlier diagnosis. J Inherit Metab Dis. 2005;28(4):473–478.
9. Tsukahara M, Imaizumi K, Kawai S, Kajii T. Occipital horn syndrome: report of a patient and review of the literature. Clin Genet.
1994;45(1):32–35.
10. Horn N, Morton NE, Rao DC. Genetic epidemiology of Menkes
disease. Genet Epidemiol. 1986;3(4):225–230.
11. Kapur S, Higgins JV, Delp K, Rogers B. Menkes syndrome in a girl
with X-autosome translocation. Am J Med Genet. 1987;26(2):503–510.
12. Sirleto P, Surace C, Santos H, et al. Lyonization effects of the t(X; 16)
translocation on the phenotypic expression in a rare female with MD.
Pediatr Res. 2009;65(3):347–351.
13. Desai V, Donsante A, Swoboda KJ, Martensen M, Thompson J, Kaler SG.
Favorably skewed X-inactivation accounts for neurological sparing in
female carriers of Menkes disease. Clin Genet. 2011;79(2):176–182.
14. Moller LB, Lenartowicz M, Zabot MT, et al. Clinical expression of
Menkes disease in females with normal karyotype. Orphanet J Rare
Dis. 2012;7:6.
15. Linder MC. The Biochemistry of Copper. New York, NY: Plenum Press;
1991:73–134.
16. Linder MC, Wooten L, Cerveza P, Cotton S, Shulze R, Lomeli N.
Copper transport. Am J Clin Nutr. 1998;67(5 suppl):S965–S971.

Journal of Multidisciplinary Healthcare 2016:9

Menkes disease: what a multidisciplinary approach can do
17. Vuori E, Kuttunen P. The concentrations of copper and zinc in human
milk. A longitudinal study. Acta Paediatr Scand. 1979;68(1):33–37.
18. Wapnir RA. Copper absorption and bioavailability. Am J Clin Nutr.
1998;67(5 Suppl):1054–1060.
19. Turnlund JR, Keyes WR, Anderson HL, Acord LL. Copper absorption
and retention in young men at three levels of dietary copper using the
stable isotope, 65Cu. Am J Clin Nutr. 1989;49(5):870–878.
20. Scott KC, Turnlund JR. Compartment model of copper metabolism
in adult men. J Nutr Biochem. 1994;5(7):342–350.
21. Horn N, Tumer Z. Menkes disease and the occipital horn syndrome. In:
Royce PM, Steinmann B, editors. Connective Tissue and its Heritable
Disorders: Molecular, Genetic, and Medical Aspects. New York, NY:
John Wiley and Sons Inc; 2002:651–685.
22. Lee J, Penna MM, Nose Y, Thiele DJ. Biochemical characterization
of the human copper transporter Ctr1. J Biol Chem. 2002;277(6):
4380–4387.
23. Formigari A, Irato P, Santon A. Zinc, antioxidant systems and metallothionein in metal mediated-apoptosis: biochemical and cytochemical
aspects. Comp Biochem Physiol C Toxicol Pharmacol. 2007;146(4):
443–459.
24. Speisky H, Gómez M, Burgos-Bravo F, et al. Generation of superoxide radicals by copper-glutathione complexes: redox-consequences
associated with their interaction with reduced glutathione. Bioorg
Med Chem. 2009;17(5):1803–1810.
25. Hamza I, Prohaska J, Gitlin JD. Essential role for Atox1 in the coppermediated intracellular trafficking of the Menkes ATPase. Proc Natl
Acad Sci USA. 2003;100(3):1215–1220.
26. Turski ML, Thiele DJ. New roles for copper metabolism in cell proliferation, signaling, and disease. J Biol Chem. 2009;284(2):717–721.
27. Culotta VC,Yang M, O’Halloran TV. Activation of superoxide dismutases:
putting the metal to the pedal. Biochim Biophys Acta. 2006;1763(7):
747–758.
28. Camakaris J, Petris MJ, Bailey L, et al. Gene amplification of the
Menkes (MNK; ATP7A) P-type ATPase gene of CHO cells is associated with copper resistance and enhanced copper efflux. Hum Mol
Genet. 1995;4(11):2117–2123.
29. Monty JF, Llanos RM, Mercer JF, Kramer DR. Copper exposure
induces trafficking of the Menkes protein in intestinal epithelium of
ATP7A transgenic mice. J Nutr. 2005;135(12):2762–2766.
30. Jankov RP, Boerkoel CF, Helimann J, et al. Lethal neonatal Menkes’
disease with severe vasculopathy and fractures. Acta Paediatr.
1998;87(12):1297–1300.
31. El Meskini R, Crabtree KL, Cline LB, Mains RE, Eipper BA, Ronnett GV.
ATP7A (Menkes protein) functions in axonal targeting and synaptogenesis. Mol Cell Neurosci. 2007;34(3):409–421.
32. Schlief ML, West T, Craig AM, Holtzman DM, Gitlin JD. Role of the
Menkes copper- transporting ATPase in NMDA receptor-mediated neuronal toxicity. Proc Natl Acad Sci U S A. 2006;103(40):14919–14924.
33. Kaler SG, Goldstein DS, Holmes C, Salerno JA, Gahl WA. Plasma
and cerebrospinal fluid neurochemical pattern in Menkes disease. Ann
Neurol. 1993;33(2):171–175.
34. Kennerson ML, Nicholson GA, Kaler SG, et al. Missense mutations
in the copper transporter gene ATP7A cause X-linked distal hereditary
motor neuropathy. Am J Hum Genet. 2010;86(3):343–352.
35. Qin Z, Gongora MC, Ozumi K, et al. Role of Menkes ATPase in
angiotensin II-induced hypertension a key modulator for extracellular
superoxide dismutase function. Hypertension. 2008;52(5):945–951.
36. Rabik CA, Maryon EB, Kasza K, Shafer JT, Bartnik CM, Dolan ME.
Role of copper transporters in resistance to platinating agents. Cancer
Chemother Pharmacol. 2009;64(1):133–142.
37. White C, Lee J, Kambe T, Fritsche K, Petris MJ. A role for the ATP7A
copper transporting ATPase in macrophage bactericidal activity. J Biol
Chem. 2009;284(49):33949–33956.
38. Kim BE, Turski ML, Nose Y, Casad M, Rockman HA, Thiele DJ.
Cardiac copper deficiency activates a systemic signaling mechanism
that communicates with the copper acquisition and storage organs.
Cell Metab. 2010;11(5):353–363.

submit your manuscript | www.dovepress.com

Dovepress

Powered by TCPDF (www.tcpdf.org)

383

Ojha and Prasad
39. Horn N. Copper incorporation studies on cultured cells for prenatal
diagnosis of Menkes’ disease. Lancet. 1976;307(7970):1156–1158.
40. Verga V, Hall BK, Wang SR, Johnson S, Higgins JV, Glover TW.
Localization of the translocation breakpoint in a female with Menkes
syndrome to Xq13.2-q13.3 proximal to PGK-1. Am J Hum Genet.
1991;48(6):1133–1138.
41. Tumer Z, Tommerup N, Tonnesen T, Kreuder J, Craig IW, Horn N.
Mapping of the Menkes locus to Xq13.3 distal to the X-inactivation
center by an intrachromosomal insertion of the segment Xq13.3-q21.2.
Hum Genet. 1992;88(6):668–672.
42. Chelly J, Tumer Z, Tonnesen T, et al. Isolation of a candidate gene for
Menkes disease that encodes a potential heavy metal binding protein.
Nat Genet. 1993;3(1):14–19.
43. Mercer JA, Livingston J, Hall B, et al. Isolation of a partial candidate
gene for Menkes disease by positional cloning. Nat Genet. 1993;
3(1):20–25.
44. Vulpe C, Levinson B, Whitney S, Packman S, Gitschier J. Isolation
of a candidate gene for Menkes disease and evidence that it encodes
a copper-transporting ATPase. Nat Genet. 1993;3(1):7–13.
45. Stenson PD, Mort M, Ball EV, et al. The human gene mutation database:
2008 update. Genome Med. 2009;1(1):13.
46. Gu YH, Kodama H, Murata Y, et al. ATP7A gene mutations in 16
patients with Menkes disease and a patient with occipital horn syndrome. Am J Med Genet. 2001;99(3):217–222.
47. Kaler SG, Liew CJ, Donsante A, Hicks JD, Sato S, Greenfield JC.
Molecular correlates of epilepsy in early diagnosed and treated Menkes
disease. J Inherit Metab Dis. 2010;33(5):583–589.
48. Tumer Z, Moller LB, Horn N. Screening of 383 unrelated patients
affected with Menkes disease and finding of 57 gross deletions in
ATP7A. Hum Mutat. 2003;22(6):457–464.
49. Kaler SG. Inborn errors of copper metabolism. Handb Clin Neurol.
2013;113:1745–1754.
50. Tumer Z. An overview and update of ATP7A mutations leading to
Menkes disease and occipital horn syndrome. Hum Mutat. 2013;34(3):
417–429.
51. Kaler SG. Metabolic and molecular bases of Menkes disease and
occipital horn syndrome. Pediatr Dev Pathol. 1998;1(1):85–98.
52. Dagenais SL, Adam AN, Innis JW, Glover TW. A novel frameshift mutation in exon 23 of ATP7A (MNK) results in occipital horn syndrome
and not in Menkes disease. Am J Hum Genet. 2001;69(2):420–427.
53. Moizard MP, Ronce N, Blesson S, et al. Twenty-five novel mutations
including duplications in the ATP7A gene. Clin Genet. 2011;79(3):
243–253.
54. Kaler SG. ATP7A-related copper transport diseases-emerging concepts
and future trends. Nat Rev Neurol. 2011;7(1):15–29.
55. Kodoma H, Murata Y, Kobayashi M. Clinical manifestations
and treatment of Menkes disease and its variants. Pediatr Int.
1999;41(4):423–429.
56. Grange DK, Kaler SG, Albers GM, Petterchak JA, Thorpe CM,
DeMello DE. Severe bilateral panlobular emphysema and pulmonary
arterial hypoplasia: unusual manifestations of Menkes disease. Am J
Med Genet A. 2005;139(2):151–155.
57. Gu YH, Kodama H, Kato T. Congenital abnormalities in Japanese
patients with Menkes disease. Brain Dev. 2012;34(9):746–749.
58. Moore CM, Howell RR. Ectodermal manifestations in Menkes disease.
Clin Genet. 1985;28(6):532–540.
59. Mizuguchi M, Itoh M, Ozawa H, Morikawa Y. A 2-year-old boy with
hypoactivity of neonatal onset and profound developmental delay.
Neuropathology. 2007;27(2):145–149.
60. Daish P, Wheeler EM, Roberts PF, Jones RD. Menkes syndrome: report
of a patient treated from 21 days of age with parenteral copper. Arch
Dis Child. 1978;53(12):956–958.
61. Sasaki G, Ishii T, Sato S, et al. Multiple polypoid masses in the gastrointestinal tract in patient with Menkes disease on copper- histidinate
therapy. Eur J Pediatr. 2004;163(12):745–746.
62. Okada T, Sasaki F, Honda S, Miyagi H, Kubota M, Todo S. Menkes disease with gastroesophageal reflux disease and successful surgical treatment: a case report and literature. Turk J Pediatr. 2010;52(3):333–335.

384

Powered by TCPDF (www.tcpdf.org)

submit your manuscript | www.dovepress.com

Dovepress

Dovepress
63. Shiihara T, Kato M, Honma T, et al. Progressive sliding hiatal hernia as a
complication of Menkes’ syndrome. J Child Neurol. 2002;17(5):401–402.
64. Sartoris DJ, Luzzatti L, Weaver DD, Macfarlane JD, Hollister DW, Parker
BR. Type IX Ehlers-Danlos syndrome. A new variant with pathognomonic radiographic features. Radiology. 1984;152(3):665–670.
65. Kaler SG, Westman JA, Bernes SM, et al. Gastrointestinal hemorrhage associated with gastric polyps in Menkes disease. J Pediatr.
1993;122(1):93–95.
66. Jeong GU, Cho A, Hwang H, et al. A case of Menkes disease with
unusual hepatomegaly. Korean J Pediatr. 2008;51(5):538–541.
67. Royce PM, Steinmann B. Markedly reduced activity of lysyl oxidase
in skin and aorta from a patient with Menkes disease showing unusually severe connective tissue manifestations. Pediatr Res. 1990;28(2):
137–141.
68. Royce PM, Camakaris J, Danks DM. Reduced lysyl oxidase activity
in skin fibroblast from patients with Menkes syndrome. Biochem J.
1980;192(2):579–586.
69. Menkes JH. Kinky hair disease: twenty five years later. Brain Dev.
1988;10(2):77–79.
70. Menkes JH. Kinky hair disease. Pediatrics. 1972;50(2):181–183.
71. Grover WD, Johnson WC, Henkin RI. Clinical and biochemical aspects
of trichopoliodystrophy. Ann Neurol. 1979;5(1):65–71.
72. Smith VV, Anderson G, Malone M, Sebire NJ. Light microscopic
examination of scalp hair samples as an aid in the diagnosis of pediatric
disorders: retrospective review of more than 300 cases from a single
centre. J Clin Pathol. 2005;58(12):1294–1298.
73. Whiting DA. Structural abnormalities of the hair shaft. J Am Acad
Dermatol. 1987;16(1 pt 1):1–25.
74. Kaler SG. Diagnosis and therapy of Menkes syndrome, a genetic form
of copper deficiency. Am J Clin Nutr. 1998;67(suppl 5):S1029–S1034.
75. Kaler SG, Holmes CS, Goldstein DS. Dopamine beta-hydroxylase
deficiency associated with mutations in a copper transporter gene.
Adv Pharmacol. 1998;42:66–68.
76. Robain O, Aubourg P, Routon MC, Dulac O, Ponsot G. Menkes disease:
a Golgi and electron microscopic study of the cerebellar cortex. Clin
Neuropathol. 1988;7(2):47–52.
77. Bindu PS, Taly AB, Kothari S, et al. Electro-clinical features and
magnetic resonance imaging correlates in Menkes disease. Brain Dev.
2013;35(5):398–405.
78. Bahi-Buisson N, Kaminska A, Nabbout R, et al. Epilepsy in Menkes
disease: analysis of clinical stages. Epilepsia. 2006;47(2):380–386.
79. Jayawant S, Halpin S, Wallace SG. Menkes kinky hair disease: an
unusual case. Eur J Pediatr Neurol. 2000;4(3):131–134.
80. Friedman ET, Harden A, Koivikko M, Pampiglione G. Menkes’disease:
neurophysiological aspects. J Neurol Neurosurg Psychiatry.
1978;41(6):505–510.
81. White SR, Reese K, Sato S, Kaler SG. Spectrum of EEG findings in
Menkes disease. Electroencephalogr Clin Neurophysiol. 1993;87(1):
57–61.
82. Kaler SG, Holmes CS, Goldstein DS, et al. Neonatal diagnosis and
treatment of Menkes disease. N Engl J Med. 2008;358(6):605–614.
83. Barnard RO, Best PV, Erdohazi M. Neuropathology of Menkes’ disease.
Dev Med Child Neurol. 1978;20(5):586–597.
84. Okeda R, Gei S, Chen I, Okaniwa M, Shinomiya M, Matsubara O.
Menkes’ kinky hair disease: morphological and immunohistochemical comparison of two autopsied patients. Acta Neuropathol.
1991;81(4):450–457.
85. Proud VK, Mussell HG, Kaler SG, Young DW, Percy AK. Distinctive
Menkes disease variant with occipital horns: delineation of natural
history and clinical phenotype. Am J Med Genet. 1996;65(1):44–51.
86. Herman TE, McAlister WH, Boniface A, Whyte MP. Occipital horn
syndrome. Pediatr Radiol. 1992;22(5):363–365.
87. Danks DM. The mild form of Menkes disease: progress report on the
original case. Am J Med Genet. 1988;30(3):859–864.
88. Gerdes AM, Tønnesen T, Pergament E, et al. Variability in clinical
expression of Menkes syndrome. Eur J Pediatr. 1988;142(2):132–135.
89. Westman JA, Richardson DC, Rennert OM, Morrow G 3rd. Atypical
Menkes steely hair disease. Am J Med Genet. 1998;30(3):853–858.
Journal of Multidisciplinary Healthcare 2016:9

Dovepress
90. Møller LB, Mogensen M, Horn N. Molecular diagnosis of Menkes disease:
genotype-phenotype correlation. Biochimie. 2009;91(10):1273–1277.
91. Tümer Z, Lund C, Tolshave J, Vural B, Tønnesen T, Horn N. Identification of point mutations in 41 unrelated patients affected with Menkes
disease. Am J Hum Genet. 1997;60(1):63–71.
92. Das S, Levinson B, Whitney S, Vulpe C, Packman S, Gitschier J.
Diverse mutations in patients with Menkes disease often lead to exon
skipping. Am J Hum Genet. 1994;55(5):883–889.
93. Kaler SG, Gahl WA, Berry SA, Holmes CS, Goldstein DS. Predictive
value of plasma catecholamine levels in neonatal detection of Menkes
disease. J Inherit Metab Dis. 1993;16(5):907–908.
94. Kaler SG, Tumer Z. Prenatal diagnosis of Menkes disease. Prenat
Diagn. 1998;18(3):287–289.
95. Tønnesen T, Gerdes AM, Damsgaard E, et al. First-trimester diagnosis
of Menkes disease: intermediate copper values in chorionic villi from
three affected male fetuses. Prenat Diagn. 1989;9(3):159–165.
96. Vonk WI, Wijmenga C, van de Sluis B. Relevance of animal models
for understanding mammalian copper homeostasis. Am J Clin Nutr.
2008;88(suppl 3):S840–S845.
97. Lenartowicz M, Krzeptowski W, Lipinski P, et al. Mottled mice and
non-mammalian models of Menkes disease. Front Mol Neurosci.
2015;8:72.
98. Fraser AS, Nay T. Growth of the mouse coat. II. Effect of sex and
pregnancy. Aust J Biol Sci. 1953;6(4):645–656.
99. Hunt DM. Primary defect in copper transport underlies mottled mutants
in the mouse. Nature. 1974;249(460):852–854.
100. Tanaka K, Kobayashi K, Fujita Y, Fukuhara C, Onosaka S, Min K.
Effects of chelators on copper therapy of macular mouse, a model animal of Menkes’ kinky disease. Res Commun Chem Pathol Pharmacol.
1990;69(2):217–227.
101. Kodama H, Sato E, Gu YH, Shiga K, Fujisawa C, Kozuma T. Effect
of copper and diethyldithiocarbamate combination therapy on the
macular mouse, an animal model of Menkes disease. J Inherit Metab
Dis. 2005;28(6):971–978.
102. Lenartowicz M, Krzeptowski W, Koteja P, Chrzascik K, Moller LB.
Prenatal treatment of mosaic mice (Atp7a mo-ms) mouse model for
Menkes disease, with copper combined by dimethyldithiocarbamate
(DMDTC). PLoS One. 2012;7(7):e40400.
103. Mendelsohn BA, Yin C, Johnson SL, Wilm TP, Solnica-Krezel L, Gitlin
JD. Atp7a determines a hierarchy of copper metabolism essential for
notochord development. Cell Metab. 2006;4(2):155–162.
104. Madsen EC, Morcos PA, Mendelsohn BA, Gitlin JD. In vivo correction
of a Menkes disease model using antisense oligonucleotides. Proc Natl
Acad Sci U S A. 2008;105(10):3909–3914.

Menkes disease: what a multidisciplinary approach can do
105. Norgate M, Lee E, Southon A, et al. Essential roles in development
and pigmentation for the Drosophila copper transporter DmATP7.
Mol Biol Cell. 2006;17(1):475–484.
106. Bahadorani S, Bahadorani P, Marcon E, Walker DW, Hilliker AJ. A Drosophila model of Menkes disease reveals a role for DmATP7 in copper
absorption and neurodevelopment. Dis Model Mech. 2010;3(1–2):
84–91.
107. Staphanede A, Giorgi M, Attilakos A, Papadopoulos J, Tsirouda M,
Dinopoulos A. Late onset treatment on Menkes disease with a novel
single nucleotide deletion in the ATP7A gene. Eur J Pediatr Neurol.
2015;19:S121.
108. Tchan MC, Wilchen B, Christodoulou J. The mild form of Menkes
disease: a 34 year progress report on the original case. JIMD Rep.
2013;9:81–84.
109. Sander C, Niederhoff H, Horn N. Life-span and Menkes kinky hair
syndrome: report of a 13- year course of this disease. Clin Genet.
1988;33(3):228–233.
110. Kaler SG, Das S, Levinson B, et al. Successful early copper therapy
in Menkes disease associated with a mutant transcript containing a
small in-frame deletion. Biochem Mol Med. 1996;57(1):37–46.
111. Christodoulou J, Danks DM, Sarkar B, et al. Early treatment of MD
with parenteral copper -histidine: long-term follow-up of four treated
patients. Am J Med Genet. 1998;76(2):154–164.
112. Kaler SG. Neurodevelopment and brain growth in classic MD is influenced by age and symptomatology at initiation of copper treatment.
J Trace Elem Med Biol. 2014;28(4):427–430.
113. Prasad AN, Levin S, Rupar CA, Prasad C. Menkes disease and infantile
epilepsy. Brain Dev. 2011;33(10):866–876.
114. Tang J, Donsante A, Desai V, Patronas N, Kaler SG. Clinical outcomes
in Menkes disease patients with a copper-responsive ATP7A mutation,
G727R. Mol Genet Metab. 2008;95(3):174–181.
115. Sherwood G, Sarkar B, Kortsak AS. Copper histidinate therapy
in Menkes’ disease: prevention of progressive neurodegeneration.
J Inherit Metab Dis. 1989;12(2):393–396.
116. Kaler SG. Menkes disease mutations and response to early copper
histidine treatment. Nat Genet. 1996;13(1):21–22.
117. Nassogne M-C, Sharrad M, Hertz-Pannier L, et al. Massive subdural
haematomas in Menkes disease mimicking shaken baby syndrome.
Childs Nerv Syst. 2002;18(12):729–731.
118. Jain P, Sharma S, Sankhyan N, et al. Macrocephaly with diffuse white
matter changes simulating a leukodystrophy in Menkes disease. Indian
J Pediatr. 2013;80(2):160–162.
119. Saha S, Mridha D. An unusual cause for focal convulsions: Menkes
kinky hair disease. J Pediatr Neurol. 2013;11(02):123–125.

Dovepress

Journal of Multidisciplinary Healthcare

Publish your work in this journal
The Journal of Multidisciplinary Healthcare is an international, peerreviewed open-access journal that aims to represent and publish research
in healthcare areas delivered by practitioners of different disciplines. This
includes studies and reviews conducted by multidisciplinary teams as well
as research which evaluates the results or conduct of such teams or health-

care processes in general. The journal covers a very wide range of areas and
welcomes submissions from practitioners at all levels, from all over the world.
The manuscript management system is completely online and includes a
very quick and fair peer-review system. Visit http://www.dovepress.com/
testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/journal-of-multidisciplinary-healthcare-journal

Journal of Multidisciplinary Healthcare 2016:9

submit your manuscript | www.dovepress.com

Dovepress

Powered by TCPDF (www.tcpdf.org)

385

